Research
Hormonal
Peripheral administration of Peptide YY (PYY) (3-36) reduces food intake and body weight gain in rodents and reduces appetite in humans, primarily by acting on Y2 receptors in the arcuate nucleus and via vagal afferent signaling.
Peripheral PYY administration reduces food intake in both lean and obese humans. This suggests that therapies mimicking PYY (like GLP-1 agonists which often co-secreted with PYY) can help manage appetite by leveraging the body's natural satiety hormones.
GoodSupportsHIGH confidence
Peripheral PYY administration causes a decrease in food intake and body weight gain in rats [63]. Similarly, in both lean and obese humans, PYY infusion reduces appetite and food intake [63, 64].
Why this rating
The paper cites multiple human and animal studies showing consistent anorectic effects, though it notes conflicting data on baseline circulating levels in obese vs lean subjects.
Source
The role of gut hormones and the hypothalamus in appetite regulation
Keisuke Suzuki et al. · Endocrine Journal · 2010
DOI 10.1507/endocrj.k10e-077
narrative_reviewCited 315×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gastric bypass surgery leads to sustained weight loss, partly mediated by a decrease in circulating ghrelin and an increase in peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) levels.Good
- Peripheral administration of Glucagon-like peptide-1 (GLP-1) reduces food intake in a dose-dependent manner in both normal weight and obese subjects, although obese subjects have a blunted postprandial GLP-1 response.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →